Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations
ReviewHumans
- Design
- Review
- Subjects
- 48 studies, of which 47 were randomised controlled trials
- Dose used in the study
- The included trials used about 150 to 700 mg, once or twice a day
- Duration
- From 3 days to 53 weeks
- What was measured
- What the randomised trial evidence shows for palmitoylethanolamide across patient populations: neuropsychiatric, neurological, bodily pain and function, gut and internal organ, and blood marker outcomes, following PRISMA 2020 methodology.
What the authors reported
The review covered 47 randomised controlled trials (48 eligible outputs), spanning neuropsychiatric (15), neurological (17), somatic (13) and visceral (11) conditions, plus 10 trials measuring blood, plasma or tissue biomarkers. The strongest evidence was for pain management and general wellbeing, especially with ultramicronized, micronized or cold-water dispersible formulations. Most included trials rated good quality on the Joanna Briggs Institute tool, two rated fair. Palmitoylethanolamide was well tolerated across the trials, with no relevant adverse events.
Limits of this study
A systematic review without a pooled analysis. The authors state that the trials differ in method and in formulation, which makes them hard to compare. The entry was checked against the article page and the Crossref record. One author (Colizzi) declares consulting for GW Pharma and Roche, outside this work; the others declared no conflict. Funding was not visible on the page checked.
Source
PubMed 39839988 · doi:10.1016/j.bbih.2024.100927
Entry checked against the article page at the publisher (ScienceDirect), with the citation from Crossref on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.